Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - propranolol hydrochloride, quantity: 160 mg - tablet, film coated - excipient ingredients: magnesium stearate; calcium carbonate; croscarmellose sodium; gelatin; pregelatinised maize starch; titanium dioxide; hypromellose; sunset yellow fcf; erythrosine; macrogol 400 - 1. angina pectoris. 2. hypertension. 3. prevention of migraine. 4. cardiac dysrythmias: certain intrinsic cardiac dysrythmias; dysrythmias associated with thyrotoxicosis; anxiety tachycardia; certain drug induced dysrythmias (eg. tachycardia due to digitalis or adrenaline overdosage). 5. essential tremor including familial and senile tremor. 6. phaeochromocytoma (only with concurrent alpha antagonist). 7. hypertrophic subaortic stenosis. 8. suspected or definite myocardial infarction.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - propranolol hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; croscarmellose sodium; calcium carbonate; magnesium stearate; gelatin; titanium dioxide; hypromellose; sunset yellow fcf; erythrosine; macrogol 400 - 1. angina pectoris. 2. hypertension. 3. prevention of migraine. 4. cardiac dysrythmias: certain intrinsic cardiac dysrythmias; dysrythmias associated with thyrotoxicosis; anxiety tachycardia; certain drug induced dysrythmias (eg. tachycardia due to digitalis or adrenaline overdosage). 5. essential tremor including familial and senile tremor. 6. phaeochromocytoma (only with concurrent alpha antagonist). 7. hypertrophic subaortic stenosis. 8. suspected or definite myocardial infarction.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: water for injections - ephedrine hydrochloride injection is indicated in the treatment of hypotension secondary to spinal anaesthesia.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

par pharmaceutical, inc. - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride 120 mg - diltiazem hydrochloride extended-release capsules, usp is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive medications. diltiazem hydrochloride extended-release capsules, usp is indicated for the management of chronic stable angina and angina due to coronary artery spasm. diltiazem hydrochloride tablets are contraindicated in (1) patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker, (2) patients with second- or third-degree av block except in the presence of a functioning ventricular pacemaker, (3) patients with hypotension (less than 90 mm hg systolic), (4) patients who have demonstrated hypersensitivity to the drug, and (5) patients with acute myocardial infarction and pulmonary congestion documented by x-ray on admission.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

american health packaging - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride 120 mg - diltiazem hydrochloride extended-release capsules, usp is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive medications. diltiazem hydrochloride extended-release capsules, usp is indicated for the management of chronic stable angina and angina due to coronary artery spasm. diltiazem hydrochloride tablets are contraindicated in (1) patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker, (2) patients with second- or third-degree av block except in the presence of a functioning ventricular pacemaker, (3) patients with hypotension (less than 90 mm hg systolic), (4) patients who have demonstrated hypersensitivity to the drug, and (5) patients with acute myocardial infarction and pulmonary congestion documented by x-ray on admission.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

physicians total care, inc. - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - propranolol hydrochloride 60 mg - hypertension propranolol hydrochloride extended-release capsules are indicated in the management of hypertension. it may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. propranolol hydrochloride extended-release capsules is not indicated in the management of hypertensive emergencies. angina pectoris due to coronary atherosclerosis propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. migraine propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of common migraine headache. the efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. hypertrophic subaortic stenosis propranolol hydrochloride extended-release capsules improves nyha functional class in symptomatic patients with hypertrophic subaortic stenosis. propranolol is

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quinapril hydrochloride, quantity: 21.664 mg (equivalent: quinapril, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; magnesium stearate; colloidal anhydrous silica; povidone; calcium sulfate dihydrate; crospovidone; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quinapril hydrochloride, quantity: 10.832 mg (equivalent: quinapril, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; calcium sulfate dihydrate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quinapril hydrochloride, quantity: 5.416 mg (equivalent: quinapril, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; povidone; calcium sulfate dihydrate; magnesium carbonate hydrate; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 240 mg - capsule, modified release - excipient ingredients: ethylcellulose; simethicone; purified talc; castor oil; tributyl acetylcitrate; white beeswax; methacrylic acid copolymer; titanium dioxide; gelatin; colloidal anhydrous silica; brilliant blue fcf; stearic acid; fumaric acid; maize starch; sucrose - diltiazem sandoz cd is indicated for the treatment of hypertension. diltiazem sandoz cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina has not been substantiated, use of this formulation for these indications is not recommended.